Suicide — Training General Practitioners in Bulgaria to Reduce Suicide Rate
Citation(s)
du Roscoät E, Beck F Efficient interventions on suicide prevention: a literature review. Rev Epidemiol Sante Publique. 2013 Aug;61(4):363-74. doi: 10.1016/j.respe.2013.01.099. Epub 2013 Jul 10. Review.
Fenwick CD, Vassilas CA, Carter H, Haque MS Training health professionals in the recognition, assessement and management of suicide risk. Int J Psychiatry Clin Pract. 2004;8(2):117-21. doi: 10.1080/13651500410005658.
Hegerl U, Althaus D, Schmidtke A, Niklewski G The alliance against depression: 2-year evaluation of a community-based intervention to reduce suicidality. Psychol Med. 2006 Sep;36(9):1225-33. Epub 2006 May 17.
Luoma JB, Martin CE, Pearson JL Contact with mental health and primary care providers before suicide: a review of the evidence. Am J Psychiatry. 2002 Jun;159(6):909-16. Review.
Pfaff JJ, Acres JG, McKelvey RS Training general practitioners to recognise and respond to psychological distress and suicidal ideation in young people. Med J Aust. 2001 Mar 5;174(5):222-6.
Robinson J, Hetrick SE, Martin C Preventing suicide in young people: systematic review. Aust N Z J Psychiatry. 2011 Jan;45(1):3-26. doi: 10.3109/00048674.2010.511147. Review.
Rutz W, von Knorring L, Wålinder J Long-term effects of an educational program for general practitioners given by the Swedish Committee for the Prevention and Treatment of Depression. Acta Psychiatr Scand. 1992 Jan;85(1):83-8.
WHO Suicide rates, age-standardized. Data by country [https://web.archive.org/web/20180117045516/http://apps.who.int/gho/data/node.main.MHSUICIDEASDR?lang=en]. 2015.
WHO Suicide rates. Data by country [http://apps.who.int/gho/data/node.main.MHSUICIDE?lang=en]. 2015.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
